Rui Therapeutics
Next-generation cell therapies for autoimmune and inflammatory diseases
About Rui Therapeutics
Rui Therapeutics, established in June 2021, is a clinical-stage biopharmaceutical company focused on developing new drugs based on next-generation cell therapies. The company was co-founded by Dr. Qian Hao, who serves as CEO, alongside other overseas scientists and executives from multinational pharmaceutical firms. Their mission is to create innovative treatments using core technologies with independent intellectual property rights.
The firm has established three main technology platforms: a CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapy platform, a therapeutic single-base gene editing platform, and a small molecule-induced regenerative medicine platform. Rui Therapeutics has developed proprietary technologies such as the HTAS-RV™ viral delivery system and CRA-NKTM taming technology. Its primary focus is on developing first-in-class pipeline products for indications with significant unmet clinical needs, including autoimmune diseases, tumors, inflammatory diseases, central nervous system disorders, and anti-aging.
Rui Therapeutics' lead candidate, KN5501, is a CAR-NK cell therapy for Systemic Lupus Erythematosus (SLE) that received IND approval in China in September 2025. In collaboration with Shanghai Changhai Hospital, early clinical data from researcher-initiated trials (IIT) for KN5501 has demonstrated good efficacy and safety in treating severe SLE patients. The company's pipeline also includes treatments for other autoimmune conditions and various cancers, with several products in IIT clinical trials.
The company has secured significant funding to advance its pipeline. In July 2023, it completed a Pre-A financing round of tens of millions of RMB. More recently, in September 2025, Rui Therapeutics announced a Series A financing round exceeding CNY 200 million, co-led by several prominent venture capital firms. This capital is being used to support IND submissions, advance pipeline products, and expand research and development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Autoimmune, Inflammatory Diseases, Cell Therapy, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $28M | $110M | Nanshan Strategic Emerging · Shenzhen Capital Group · Wanbang Pharmaceutical Technology · Nanshan Venture Capital | ↗ |
| SEED✓Equity / VC | Jul 2023 | $2.8M | $11M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Rui Therapeutics is 140 monthly website visits, down 30% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Rui Therapeutics in the Nanjing City ecosystem
The Rui Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Shenzhen Capital Group
Green Pine Capital- NENanshan Strategic Emerging
- WTWanbang Pharmaceutical Technology
- NCNanshan Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rui Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rui Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








